Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney cancer drug use under the microscope in belgian study

NCT ID NCT04106349

Knowledge-focused Sponsor: Ipsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 02, 2026 · Updated 7 times

Summary

This study tracks how 150 patients in Belgium use the drug cabozantinib (Cabometyx), alone or with nivolumab, for advanced or metastatic kidney cancer. It looks at real-world dosing, treatment changes, and quality of life. The goal is to understand how these treatments are actually used outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabozantinib (Cabometyx) alone or with nivolumab
What this could lead to
If successful, this study could provide real-world insights into how cabozantinib is used and tolerated in routine care for advanced kidney cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

advanced or metastatic renal cell carcinoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females aged 18 years and older * Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma * Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study * Provision of written informed consent Exclusion Criteria: * Participation in another interventional clinical study at the same time * Previous participation in this clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced or metastatic renal cell carcinoma

Contacts and locations

Locations

  • AZ Delta

    Roeselare, 8800, Belgium

  • AZ Glorieux

    Ronse, 9600, Belgium

  • AZ Sint-Jan Brugge

    Bruges, 8000, Belgium

  • AZ Sint-Lucas

    Bruges, 8310, Belgium

  • AZ Turnhout

    Turnhout, 2300, Belgium

  • CHC MontLegia

    Liège, 4000, Belgium

  • CHR Citadelle Liège

    Liège, 4000, Belgium

  • CHR Verviers

    Verviers, 4800, Belgium

  • CHU Charleroi - site André Vésale

    Montigny-le-Tilleul, 6110, Belgium

  • CHU Liège / Sart-Tilman

    Liège, 4000, Belgium

  • CHWAPI

    Tournai, 7500, Belgium

  • Clinique Saint-Luc Bouge

    Bouge, 5004, Belgium

  • Clinique Saint-Pierre

    Ottignies, 1340, Belgium

  • Hôpital Ambroise-Paré Mons

    Mons, 7000, Belgium

  • Hôpital de Jolimont

    La Louvière, 7100, Belgium

  • Imeldaziekenhuis

    Bonheiden, 2820, Belgium

  • Onze-Lieve-vrouw Ziekenhuis Aalst

    Aalst, 9300, Belgium

  • UZ Brussel

    Brussels, 1090, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

  • Ziekenhuis Oost-Limburg Genk

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.